A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease

Clinical trial NCT06996730 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06996730
Sponsor: Banner Health
Status: NOT_YET_RECRUITING
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Autosomal Dominant Alzheimers Disease Early Onset Alzheimer Disease Alzheimers Disease

Start date: 2026-01-15
Primary completion: 2030-06-01
Enrollment: 240

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.